News | January 18, 2026
JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
Experts caution that realizing AI’s potential requires careful management and risk mitigation
Projects selected for advancement will move forward through the Harvard Office of Technology Development’s processes for sponsored research agreements
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Nona aims to help global biopharmaceutical companies fast-track clinical trial initiation without compromising scientific rigor or quality standards
India plays a critical role in Bristol Myers Squibb’s global strategy
Subscribe To Our Newsletter & Stay Updated
